Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team
- Dr Mark Creighton‐Gutteridge appointed as Vice President, Head of Research
- Dr Rachel Abbott appointed as Head of TCR Pipeline and Dark Antigen Research
Oxford and London, UK – 09 March 2021. Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, announces new appointments to the senior research team to further strengthen its TCR and cell therapy capabilities. These appointments will bring additional specialized expertise and leadership to help advance the discovery and characterization of novel immunotherapy targets and develop next-generation therapies for cancer patients.
Enara has appointed Dr Mark Creighton-Gutteridge as Vice President, Head of Research. Mark brings over 17 years of experience in academia and industry, with highly relevant expertise in oncology R&D, cell therapy, and immunotherapy.
Mark joins Enara from GlaxoSmithKline (GSK) where he was Senior Director, Head of Biology, Oncology Cell Therapy R&D. Prior to his career at GSK, he worked at Cellzome AG and previous to that was a postdoctoral fellow at the National Cancer Institute in the US.
Mark will be responsible for leading Enara’s research efforts, including its cell therapy strategy, to ensure that Enara is positioned to rapidly develop the next generations of autologous and allogeneic cellular immunotherapies, including those directed against the monomorphic HLA-like receptor MR1.
Dr Rachel Abbott has been appointed as Head of TCR Pipeline and Dark Antigen Research, joining the Company from Adaptimmune, a pioneer in TCR T-cell therapy, where she was Head of Pipeline Cell Biology. Rachel brings over 14 years of experience from her time at Adaptimmune and prior to this as a Research Fellow at the University of Birmingham.
Rachel will be responsible for scaling Enara’s proprietary EDAPT™ platform, and will also oversee all TCR discovery, validation and preclinical testing to identify and progress TCRs targeting Dark Antigens along with other novel antigens into early development.
Download the press release
At Enara, we are driven by the belief that novel targets which address broader patient populations will play a vital role in developing the next generation of successful immunotherapies for solid cancers. These latest appointments confirm Enara’s ability to recruit outstanding talent to our organization, and I am very pleased to welcome Mark and Rachel to the Company. We have ambitious growth plans, building on our Dark Antigen™ and TCR discovery platforms. Mark and Rachel bring considerable experience to Enara which will help to translate our world-leading discovery expertise into a new generation of cancer immunotherapies for the benefit of broad groups of cancer patients. As Enara continues to expand we will be seeking further opportunities to enhance our team, capabilities and capacity to fully exploit our leadership position in Dark Antigens and unconventional T-cell targets including MR1.Kevin Pojasek, President and CEO of Enara Bio
About Enara Bio
Enara Bio (formerly Ervaxx) is a science-led company targeting the T-cell/cancer-cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel immunotherapy targets, such as Dark Antigens™ and MR1-presented ligands. We are pioneering approaches to exploit these targets with TCR-directed T-cell immunotherapy and therapeutic vaccines. To achieve our mission, we are leveraging our differentiated Dark Antigen™ and TCR discovery platforms that integrate bioinformatics, immunopeptidomics, metabolomics and immunology in our Oxford, UK-based research lab. Enara Bio is backed by leading life science investors, including SV Health Investors. We have partnerships with world-class academic institutions, including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive the leading edge of these new areas of science. We also have a major strategic collaboration and licensing agreement with Boehringer Ingelheim to discover novel shared antigens for cancer immunotherapies.
For more information visit: www.enarabio.com
FOR MORE INFORMATION
Enara Bio Limited
Kevin Pojasek, CEO
Tel: +44(0)1865 618 828
Citigate Dewe Rogerson
Mark Swallow, Frazer Hall, Nathaniel Dahan
Tel: +44 (0)20 7638 9571